



## Post Authorisation Assessments

For details of post authorisation assessments prior to 1<sup>st</sup> January 2021,  
please refer to the [EMA](#) website.

### Reconcile 64 mg Chewable Tablets for Dogs Vm 54790/5003

|   |                  |   |
|---|------------------|---|
| • | 22 March 2024    | Alternative container added for the finished product.   |
| • | 19 October 2023  | Minor changes to an approved test procedure for active substance for the finished product.<br>Submission of a new Ph. Eur. CEP from a new manufacturer (replacement or addition) for a non-sterile: – active substance. |
| • | 26 April 2023    | Additional site for batch testing of the finished product.<br>Minor changes to an approved test procedure for the finished product.   |
| • | 19 April 2023    | Replacement of a manufacturer of the finished product responsible for importation.<br>Replacement of a manufacturer of the finished product responsible for batch release.  |
| • | 25 January 2023  | Introduction of a re-test period for the active substance.  |
| • | 17 January 2023  | New certificate of suitability from a new manufacturer.   |
| • | 04 March 2022    | Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.   |
| • | 24 November 2021 | Changes in the qualitative and quantitative composition of the immediate packaging of the finished product for solid pharmaceutical forms.<br>Minor changes to an approved test procedure of the finished product.      |
| • | 14 October 2021  | Introduction of a new pharmacovigilance system.   |
| • | 13 July 2021     | Deletion of manufacturing site for an active substance where batch control takes place.   |
| • | 27 May 2021      | Change of MAH, from Pegasus Laboratories Ireland Limited, 10 McCurtain Hill, Clonakilty, County Cork, P85 K230 Ireland to FORTE Healthcare Ltd, 13 Ayr Road, Prestwick, South Ayrshire, KA9 1SX UK                      |